A Boston-based company has passed an important hurdle in its effort to get FDA approval for its ovarian-cancer treatment.

Black Diamond Therapeutics shows promise with BDTX-1535 for NSCLC treatment. Click here to find out why I rate BDTX stock a ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Champoins Oncology broke out of a multiyear downtrend following its Q2'25 earnings. Check out why I rate CSBR stock as a Buy.

OneOncology and Coastal Cancer Center's acquisition of radiation oncology centers aims to enhance service offerings and ...

Verastem Oncology said its treatment for recurrent low-grade serous ovarian cancer has been given priority review by the Food and Drug Administration. The new drug application for the treatment in ...

A clinical stage biopharma firm in Miami is slashing its headcount after selling its female condom business to an investment ...

Kura Oncology Inc (KURA) stock saw a decline, ending the day at $8.51 which represents a decrease of $-0.16 or -1.85% from the prior close of $8.67. The stock opened at $8.65 and touched a low of ...

Race Oncology hopes its repurposed drug candidate bisantrene can protect the heart from the dangerous effect of chemotherapy.

Recent market volatility has created an attractive entry point for both stocks heading into 2025. Their dividend yields now ...

Here are the top 5 articles from 2024 reported on Oncology Nursing News. Opinion: The Media May Have Oversold AOH1996, City ...

CURE created a list of the top breast cancer stories of this year, including those focused on patient-reported outcomes and ...